Tempest Therapeutics Registers Resale of 2.77M Shares and Warrants from Recent Private Placement
TPST is trading near its 52-week low of $1.5 (6.0% above the low).
Summary
Tempest Therapeutics filed an S-3 registration statement for the resale of 2.77 million shares of common stock and shares underlying warrants by selling stockholders, fulfilling registration rights from a recent private placement.
Key Events · Financing and Capital Events · TPST
-
Resale Registration Filed
Tempest Therapeutics registered 2,777,781 shares of common stock and shares underlying warrants for resale by selling stockholders.
-
Significant Potential Dilution
The registered shares represent approximately 19.36% of the company's outstanding common stock, creating a substantial potential for dilution.
-
Fulfills Private Placement Rights
This S-3 fulfills registration rights granted in connection with a private placement dated March 20, 2026, which included common stock, pre-funded warrants, and Series A and B warrants.
-
Company Will Not Receive Direct Proceeds
The company will not receive any proceeds from the sale of common stock by the selling stockholders, only from the potential cash exercise of warrants.
Analysis · TPST · Life Sciences
This S-3 filing registers 2.77 million shares of common stock and shares underlying warrants for resale by selling stockholders, representing approximately 19.36% of the company's current outstanding shares. These shares originate from a private placement completed on March 20, 2026, which was previously disclosed. While the underlying private placement was crucial for capital given the company's 'going concern' warning, this registration enables investors to sell their holdings, creating a significant overhang on the stock. The company will not receive proceeds from the resale of these common shares, but may receive proceeds from the cash exercise of warrants, though the common warrants are currently out-of-the-money. This substantial potential dilution is a key factor for investors to monitor.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 35.6% of the 1216 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TPST was trading at $1.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $21.8M. The 52-week trading range was $1.50 to $12.23. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.